Biologicals

Papers
(The median citation count of Biologicals is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?14
A practical approach for gmp-compliant validation of real-time PCR method for mycoplasma detection in human mesenchymal stromal cells as advanced therapy medicinal product13
Multiple antigenic peptide-based flow through dot-blot assay for simultaneous antibody detection of infectious bronchitis virus and Newcastle disease virus10
An overview of non-clinical safety studies in current Turkish regulations for the development of COVID-19 vaccines9
EGF domain peptide of Developmentally regulated endothelial locus1 facilitates gene expression of extracellularly applied plasmid DNA9
Expression profiling of inflammation-related genes including IFI-16, NOTCH2, CXCL8, THBS1 in COVID-19 patients8
Aims and Scope/Editorial Board/Publishing Details8
Report on the GHPP-BloodTrain online workshop on “Authorisation and Licensing of Blood Establishments - Review of quality documentation of blood and blood components”, 5th-8th of July 20217
Preliminary study on serum immunoglobulin G responses following intramuscular inoculation of adjuvanted polyhydroxyalkanoate microparticles with Pasteurella multocida vaccine in white rats7
Stability of lyophilized Meningococcal A conjugate vaccine, (MenAfriVac™) at elevated temperatures to support controlled temperature chain (CTC) claim7
Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges7
Development and characterization of mouse monoclonal antibodies to canine morbillivirus7
Development and evaluation of recombinant gD protein based ELISA for sero-surveillance of BoHV-1 in India7
Fourth Controlled Human Infection Model (CHIM) meeting – CHIMs in endemic countries, May 22–23, 20236
Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop6
Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization6
From discovery to innovation in animal health: Maturing emerging technologies for industrial development6
Designing multi-epitope vaccine against human cytomegalovirus integrating pan-genome and reverse vaccinology pipelines6
Corrigendum to “Comparison of Astra Zeneca and sinopharm vaccines as boosters in protection against COVID-19 infection” [Biologicals 82 (2023) 101668]5
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Reports from a series of NC3Rs stakeholder workshops5
A vision for patient-centric specifications for biologicals5
It is time to reconsider the use of naturally-occurring endotoxins in endotoxin recovery studies: Part 2 of a BioPhorum harmonized endotoxin recovery study5
Outer membrane vesicles as nanovaccine candidates against pathogenic Leptospira in experimental Guinea pig model4
Development of an ELISA for the detection of fowl adenovirus serotype −4 utilizing fiber protein4
Circulation of yellow fever virus in Benin city, Edo state Nigeria4
Development and evaluation of polymeric nanoparticles as a delivery system for snake envenoming prevention4
Aims and Scope/Editorial Board/Publishing Details4
Virus filter scalability: Demonstration of consistent viral clearance across laboratory and manufacturing scales4
Saccharide dosage content of meningococcal polysaccharide conjugate vaccines determined using WHO International Standards for serogroup A, C, W, Y and X polysaccharides4
Aims and Scope/Editorial Board/Publishing Details4
Accelerated national lot release on COVID-19 vaccines in Republic of Korea3
Viral clearance capability of monoclonal antibody purification3
Future of TABST and LABST in the Indian Pharmacopoeia Monographs A Humane Society International/India Workshop Report3
Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?3
Immunization effect of lipopolysaccharide antigen in conjugation with PLGA nanoparticles as a nanovaccine against Brucella melitensis infection3
An optimized microplate-based method to evaluate complement-dependent hemolysis mediated by intravenous immunoglobulins (IVIG)3
Development and validation of a spectrophotometric method for quantification of residual cyclodextrin (DIMEB; Heptakis) in pertussis antigens3
Glycoconjugate content quantification to assess vaccine potency: A simplified approach3
Emergence of SARS-CoV-2 variant of interest B.1.525 (Eta) in Bangladesh3
Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats3
Aims and Scope/Editorial Board/Publishing Details3
Nanoparticle formulation for the development of a dog nanovaccine against Cystic Echinococcosis3
A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency3
The development and establishment of a heat inactivated preparation of Mycobacterium tuberculosis (H37Rv) as the first international standard for nucleic acid amplification techniques3
Maintaining the quality of vaccines through the use of standards: Current challenges and future opportunities3
Adaptation and characterization of Anatid herpesvirus 1 in different permissible cell lines3
Development of a rabbit monocyte activation test as an alternative to the rabbit pyrogen test and its application in the analysis of plasma-derived products2
Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay2
Molecular characterization of Anaplasma ovis Msp4 protein in strains isolated from ticks in Turkey: A multi-epitope synthetic vaccine antigen design against Anaplasma ovis using immunoinformatic tools2
Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases2
Aims and Scope/Editorial Board/Publishing Details2
Assessment of the risks associated with the use of in vivo versus in vitro potency tests for vaccines2
Aims and Scope/Editorial Board/Publishing Details2
CDC20 is a potential target gene to inhibit the tumorigenesis of MDCK cells2
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of National Control Laboratories and National Regulatory Authorities2
WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 20212
The future of pyrogenicity testing: Phasing out the rabbit pyrogen test. A meeting report2
Development and neutralization analysis of recombinant BVDVs expressing a CSF single chain antibody in vitro2
Study on an attenuated rabies virus strain CTN181-32
Computational identification of monkeypox virus epitopes to generate a novel vaccine antigen against Mpox2
Development and validation of a novel luciferase reporter gene assay to detect pyrogen2
A collaborative study to establish the second national standard for hepatitis B immunoglobulin in Korea2
Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data2
Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine2
On-column virus inactivation by solvent/detergent treatment for a recombinant biological product2
Aims and Scope/Editorial Board/Publishing Details2
Development of an assay for detecting the residual viable virus in inactivated rabies vaccine by enzyme-linked immunosorbent assay2
Potential therapeutic effects of hAMSCs secretome on Panc1 pancreatic cancer cells through downregulation of SgK269, E-cadherin, vimentin, and snail expression2
Adjuvant effect of mesoporous silica SBA-15 on anti-diphtheria and anti-tetanus humoral immune response2
3Rs implementation in veterinary vaccine batch-release testing: Current state-of-the-art and future opportunities. A webinar and workshop report2
Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab2
Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain1
A species-independent indirect-ELISA for detection of antibodies to the non-structural protein 2B of foot-and-mouth disease virus1
Non-clinical similarity of biosimilar ABP 798 with rituximab reference product1
Canine parvovirus type 2 vaccines in Brazil: Viral load in commercial vaccine vials and phylogenetic analysis of the vaccine viruses1
Prevalence of viral agents causing swine reproductive failure in Korea and the development of multiplex real-time PCR and RT-PCR assays1
From eradication to re-emergence: The changing landscape of polio in the cVDPV2 era1
Development of an optimized RT-LAMP test for the detection of SARS-CoV-21
Regulatory workshop on challenge strain development and GMP manufacture – A stakeholder meeting report1
Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection1
Aims and Scope/Editorial Board/Publishing Details1
Virus filtration using small pore virus filter in downstream processing of biotherapeutic products: The effect of operating pressure1
Evolution of FMT – From early clinical to standardized treatments1
Validation of a next generation sequencing method for adventitious virus detection: Demonstration of sensitivity in multiple cell lines1
Determination of the experimental extinction coefficient of therapeutic proteins using the Edelhoch method1
Animal cell substrates for the production of biologicals: An introduction to WHO documents1
The contribution of field efficacy studies to the evaluation of applications for veterinary vaccines evaluated through the European Union centralised authorisation procedure1
Collaborative study on the cross-reactivity of two influenza B viral components in single radial immunodiffusion assay using quadrivalent influenza vaccines in Japan from 2015/16 to 2021–22 influenza 1
Advances in mRNA vaccine research in the field of quality control1
Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals1
Development of IgM-ELISA for diagnosis of recent infection of Japanese encephalitis virus in equines1
Evaluation of DF-1 cell culture based vaccine development for infectious bursal disease virus in Ethiopia1
Risk management for viral clearance: A case study on adoption of platform validation approach and risk management of process changes1
COVID-19: A case for plasma derived natural anticoagulants?1
The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report1
0.10105109214783